Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$161.01 - $317.85 $1.1 Million - $2.16 Million
-6,808 Reduced 66.33%
3,456 $1.09 Million
Q3 2023

Nov 14, 2023

SELL
$164.66 - $218.08 $8.18 Million - $10.8 Million
-49,673 Reduced 82.88%
10,264 $1.74 Million
Q2 2023

Aug 14, 2023

BUY
$176.32 - $240.22 $10.6 Million - $14.4 Million
59,937 New
59,937 $13 Million
Q4 2022

Feb 14, 2023

SELL
$191.53 - $236.82 $2.54 Million - $3.14 Million
-13,243 Reduced 27.69%
34,581 $6.8 Million
Q3 2022

Nov 14, 2022

BUY
$123.79 - $277.42 $5.4 Million - $12.1 Million
43,659 Added 1048.24%
47,824 $10.8 Million
Q3 2022

Nov 14, 2022

BUY
$123.79 - $277.42 $5.4 Million - $12.1 Million
43,659 Added 1048.24%
47,824 $10.8 Million
Q2 2022

Aug 16, 2022

BUY
$93.97 - $143.33 $2,819 - $4,299
30 Added 0.73%
4,165 $527,000
Q1 2022

May 17, 2022

SELL
$98.9 - $132.37 $516,554 - $691,368
-5,223 Reduced 55.81%
4,135 $524,000
Q4 2021

Feb 15, 2022

BUY
$110.64 - $159.4 $266,642 - $384,154
2,410 Added 34.69%
9,358 $1.23 Million
Q4 2020

Feb 17, 2021

SELL
$75.23 - $109.23 $287,002 - $416,712
-3,815 Reduced 35.45%
6,948 $706,000
Q3 2020

Nov 17, 2020

SELL
$71.31 - $109.74 $2.18 Million - $3.36 Million
-30,604 Reduced 73.98%
10,763 $832,000
Q2 2020

Aug 17, 2020

BUY
$62.14 - $117.21 $2.57 Million - $4.85 Million
41,367 New
41,367 $4.61 Million
Q1 2020

May 15, 2020

SELL
$60.41 - $115.92 $644,755 - $1.24 Million
-10,673 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$11.44 - $123.99 $122,099 - $1.32 Million
10,673 New
10,673 $804,000

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.